Abstract The coronavirus disease 2019 (COVID‐19) pandemic has resulted in the
reorganization of health‐care settings affecting clinical care delivery to patients with …

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated
pathology, COVID-19, have been of particular concerns these last months due to the …

Understanding the SARS-CoV-2 virus' pathways of infection, virus–host–protein interactions,
and mechanisms of virus-induced cytopathic effects will greatly aid in the discovery and …

La enfermedad producida por el SARS-CoV-2 constituye una pandemia declarada con alta
contagiosidad y letalidad en grupos de riesgo. En menos de tres meses la humanidad ha …

SARS-CoV-02 is a new type of coronavirus capable of rapid transmission and causing
severe clinical symptoms; much of which has unknown biological etiology. It has prompted …

In 2020, the world is being ravaged by the coronavirus, SARS-CoV-2, which causes a
severe respiratory disease, Covid-19. Hundreds of thousands of people have succumbed to …

Background The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in
comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest …

Abstract Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global …

En diciembre de 2019 se reportaron varios casos de neumonía, cuyo agente causal sería
denominado SARS-CoV-2 provocando la enfermedad por coronavirus (COVID-19). A pesar …

Determination of the risk–benefit ratio associated with the use of novel coronavirus disease
2019 (COVID-19) repurposed drugs in older adults with polypharmacy is mandatory. Our …